Chronic Obstructive Pulmonary Disease (COPD) 

Chronic Obstructive Pulmonary Disease (COPD)

The GSK Persist-COPD2 study is for adults with moderate to severe COPD. The disease is punctuated by acute exacerbations of COPD. The study primarily aims to demonstrate the superiority of GSK as an add on therapy in reducing annualized rate of moderate to severe COPD exacerbations.

Study information:

  • Condition: Chronic Obstructive Pulmonary Disease (COPD)

  • Location: Las Vegas, Nevada

  • Duration: Up to 112 weeks

  • Participation: Up to 16 visits

  • Compensation: Available

Eligibility:

  • Age 40 to 80 years old

  • Documented diagnosis of COPD

  • History of moderately to severely active COPD for at least 1 year

  • Currently on optimized inhaler therapy

  • Current or former cigarette smoker

  • Other study requirements apply.

Participants may receive:

  • Compensation

  • Regular health check-ins with a physician to monitor symptoms and your health

  • Tests and procedures at no-cost to you

  • Access to a potential new treatment option for Chronic Obstructive Pulmonary Disease

  • Some participants will receive placebo, which will have no effect on their condition

Get started today.

You are not committed to participate in a study by completing this form. Participation is voluntary, and you may leave at any time if you change your mind.

What is Chronic Obstructive Pulmonary Disease (COPD)?

Chronic Obstructive Pulmonary Disease (COPD) is a heterogenous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, sputum production, and/or exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction. COPD is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung.